» Articles » PMID: 30429491

Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver Resection

Overview
Journal Sci Rep
Specialty Science
Date 2018 Nov 16
PMID 30429491
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, von-Willebrand-Factor (vWF) has been shown to correlate with postoperative liver dysfunction (LD). Accordingly, "disintegrin-like metalloprotease with thrombospondin type1 motif" (ADAMTS13) is known to cleave vWF in less active fragments. Thus, we aimed to evaluate the diagnostic potential of ADAMTS13-activity (ADAMTS13-AC) to identify patients with postoperative LD after hepatectomy. Accordingly 37 patients undergoing hepatectomy for different neoplastic entities were included in this study. Plasma ADAMTS13-AC and vWF-Ag were measured 1 day prior to (preOP), 1 and 5 days (POD1/5) after hepatectomy. In accordance to the ISGLS-criteria LD was prospectively recorded. In this context, perioperative ADAMTS13-AC- and vWF-Ag/ADAMTS13-AC-ratio- levels revealed a significant increase after hepatectomy. Accordingly, elevated vWF-Ag/ADAMTS13-AC-ratio significantly predicted LD (preOP AUC: 0.75, p = 0.02; POD1 AUC: 0.80, p = 0.03). Patients who fulfilled our perioperative vWF-Ag/ADAMTS13-AC-ratio cut-off-levels (preOP: ≥116, POD1: ≥165) suffered from significantly higher incidences of LD (preOP: 70% vs. 30%, p = 0.01; POD1: 83% vs. 17%, p = 0.001). In conclusion, perioperative ADAMTS13-AC measurement may serve as a useful parameter to early detect high-risk patients developing postoperative LD prior to liver resection in patients suffering from hepatic malignancies. Indeed, further investigations have to be performed to consolidate its role as a predictive marker for LD.

Citing Articles

E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy.

Primavesi F, Maglione M, Cipriani F, Denecke T, Oberkofler C, Starlinger P Br J Surg. 2023; 110(10):1331-1347.

PMID: 37572099 PMC: 10480040. DOI: 10.1093/bjs/znad233.


Changes in Plasma Levels of ADAMTS13 and von Willebrand Factor in Patients Undergoing Elective Joint Arthroplasty.

He J, Schick S, Williams M, Wills B, Pinto M, Viner G J Clin Med. 2022; 11(21).

PMID: 36362664 PMC: 9655560. DOI: 10.3390/jcm11216436.


Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization.

Ye Z, Zheng J Front Genet. 2021; 12:660989.

PMID: 34276770 PMC: 8280495. DOI: 10.3389/fgene.2021.660989.


ADAMTS13: An Emerging Target in Stroke Therapy.

Chen X, Cheng X, Zhang S, Wu D Front Neurol. 2019; 10:772.

PMID: 31379722 PMC: 6650536. DOI: 10.3389/fneur.2019.00772.


Reply.

Starlinger P, Pereyra D, Hackl M, Assinger A Hepatology. 2019; 70(3):1082-1083.

PMID: 31032980 PMC: 6771800. DOI: 10.1002/hep.30682.

References
1.
Tsuchida T, Friedman S . Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14(7):397-411. DOI: 10.1038/nrgastro.2017.38. View

2.
Feys H, Canciani M, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P . ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007; 138(4):534-40. DOI: 10.1111/j.1365-2141.2007.06688.x. View

3.
Ding B, Cao Z, Lis R, Nolan D, Guo P, Simons M . Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature. 2013; 505(7481):97-102. PMC: 4142699. DOI: 10.1038/nature12681. View

4.
Groeneveld D, Alkozai E, Adelmeijer J, Porte R, Lisman T . Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy. Br J Surg. 2016; 103(6):735-743. DOI: 10.1002/bjs.10107. View

5.
Peyvandi F, Palla R, Lotta L, Mackie I, Scully M, Machin S . ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010; 8(4):631-40. DOI: 10.1111/j.1538-7836.2010.03761.x. View